Healthcare [ 12/13 ] | Diagnostics & Research [ 56/164 ]
NASDAQ | Common Stock
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally.
The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community.
In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits.
Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups.
Additionally, the company offers human medical point-of-care products and laboratory diagnostics services.
The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers.
IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 1, 24 | 2.81 Increased by +10.20% | 2.67 Increased by +5.24% |
| Feb 5, 24 | 2.32 Increased by +13.17% | 2.12 Increased by +9.43% |
| Nov 1, 23 | 2.53 Increased by +17.67% | 2.37 Increased by +6.75% |
| Aug 1, 23 | 2.67 Increased by +71.15% | 2.47 Increased by +8.10% |
| May 2, 23 | 2.55 Increased by +12.33% | 2.42 Increased by +5.37% |
| Feb 6, 23 | 2.05 Increased by +8.47% | 1.94 Increased by +5.67% |
| Nov 1, 22 | 2.15 Increased by +5.91% | 2.04 Increased by +5.39% |
| Aug 2, 22 | 1.56 Decreased by -33.33% | 1.56 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 964.10 M Increased by +7.10% | 235.58 M Increased by +10.06% | Increased by +24.44% Increased by +2.76% |
| Dec 31, 23 | 901.60 M Increased by +8.81% | 194.52 M Increased by +12.96% | Increased by +21.58% Increased by +3.81% |
| Sep 30, 23 | 915.53 M Increased by +8.78% | 212.23 M Increased by +17.29% | Increased by +23.18% Increased by +7.83% |
| Jun 30, 23 | 943.63 M Increased by +9.65% | 224.24 M Increased by +69.90% | Increased by +23.76% Increased by +54.94% |
| Mar 31, 23 | 900.20 M Increased by +7.61% | 214.05 M Increased by +10.36% | Increased by +23.78% Increased by +2.55% |
| Dec 31, 22 | 828.57 M Increased by +3.43% | 172.21 M Increased by +5.80% | Increased by +20.78% Increased by +2.29% |
| Sep 30, 22 | 841.66 M Increased by +3.85% | 180.94 M Increased by +3.25% | Increased by +21.50% Decreased by -0.58% |
| Jun 30, 22 | 860.55 M Increased by +4.16% | 131.98 M Decreased by -34.85% | Increased by +15.34% Decreased by -37.46% |